Effects of Rituximab on Lupus Nephritis
Author Information
Author(s): Vigna-Perez Mónica, Hernández-Castro Berenice, Paredes-Saharopulos Octavio, Portales-Pérez Diana, Baranda Lourdes, Abud-Mendoza Carlos, González-Amaro Roberto
Primary Institution: Departamento de Inmunología, Facultad de Medicina, UASLP, San Luis Potosí, SLP, México
Hypothesis
Does Rituximab therapy improve clinical and immunological outcomes in patients with lupus nephritis refractory to conventional therapy?
Conclusion
Rituximab therapy shows promise in reducing disease activity and improving certain clinical parameters in lupus nephritis patients who do not respond to standard treatments.
Supporting Evidence
- Rituximab therapy significantly reduced disease activity in 90% of patients.
- Most patients showed a decrease in proteinuria levels.
- B cell depletion was observed in 20 out of 22 patients.
- No serious adverse effects were reported in 21 out of 22 patients.
Takeaway
Rituximab is a medicine that helps some people with a kidney problem caused by lupus, making them feel better and reducing their symptoms.
Methodology
An open clinical trial was conducted with 22 patients receiving Rituximab alongside their existing immunosuppressive therapy, with evaluations at days 30, 60, and 90.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The study is limited by its small sample size and the lack of a control group.
Participant Demographics
19 females and 3 males, all diagnosed with systemic lupus erythematosus and renal involvement.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website